Appendix 3B New Issue Announcement, Application for Quotation of Additional Securities and Agreement.

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity:

Rhinomed Limited (ASX: RNO)

ACN:

107 903 159

We (the entity) give ASX the following information.

Part 1 -­‐ All issues

You must complete the relevant sections (attach sheets if there is not enough space).

Ordinary Shares (RNO)

1 +Class of +securities issued or to be issued

122,135,100 Ordinary Shares (RNO)

  1. Number of +securities issued or to be issued (if known) or maximum number which may be issued

    Fully Paid Ordinary Shares (RNO)

  2. Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if

    +convertible securities, the conversion price and dates for conversion)

    Ordinary shares rank equally with existing quoted ordinary shares.

  3. Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

    If the additional securities do not rank equally, please state:

    • the date from which they do

    • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

    • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

      122,135,000 Shares: $0.018 per Share. 100 Shares: $0.10 per Share

  4. Issue price or consideration

    122,135,000 Shares: Private Placement raising

    $2,198,430 before costs.

    100 Shares: Private Placement issued under Cleansing Prospectus.

  5. Purpose of the issue

    (If issued as consideration for the acquisition of assets, clearly identify those assets)

    Yes

    6aIs the entity an +eligible entity that has obtained security holder approval under rule 7.1A?

    If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

    8th November 2016

    6b The date the security holder resolution under rule 7.1A was passed

    122,135,100

    6c Number of +securities issued without security holder approval under rule 7.1

    Nil

    6dNumber of +securities issued with security holder approval under rule 7.1A

    Nil

    6e Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

    Nil

    6f Number of securities issued under an exception in rule 7.2

    N/A

    6g If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.

    N/A

    6h If securities were issued under rule 7.1A for non-­‐cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

    Refer to the attached Annexure 1

    6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A - complete Annexure 1 and release to ASX Market Announcements

    21 March 2017

  6. Dates of entering +securities into uncertificated holdings or despatch of certificates

    Number

    +Class

    936,369,109

    Fully Paid Ordinary Shares

    (RNO)

    203,150,000

    Listed Options (RNOOA)

    exercisable at $0.06 per

    option on or before 30 April

    2017

  7. Number and +class of all +securities quoted on ASX (including the securities in section 2 if applicable)

  8. Number and +class of all +securities not quoted on ASX (including the securities in section 2 if applicable)

    Number

    +Class (Options over Ordinary Shares)

    Amount

    Exercise Price

    Expiration Date

    ASX Code

    769,230

    $0.065

    30 April 2019

    40,000,000

    $0.065

    30 April 2017

    10,000,000

    $0.0674

    30 April 2019

    18,000,000

    $0.065

    11 April 2019

    68,769,230

    Total

    Unchanged

  9. Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Rhinomed Limited published this content on 21 March 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 22 March 2017 05:48:15 UTC.

Original documenthttp://www.rhinomed.global/wp-content/uploads/2017/03/Appendix-3B.pdf

Public permalinkhttp://www.publicnow.com/view/FC2A1FA903558DC48BE56273A8F9C1713500A4DF